With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.
787618-22-8, General procedure: After purging with argon, a scintillation vial (10 mL), which was equipped with amagnetic stir bar, was charged with RuPhos (1 equiv), the aryl containing drug or the drugderivative, and [(L5-COD)Pd(CT-iSi~1fe3)] (l. l equiv) dissolved in tetrahydrofuran (THF,0.2 M). The closed vial was purged with argon and stined for 16 h. The resulting precipitatewas tlltered, washed with pentane (3 X 3 mL), and dried under reduced pressure to afford theoxidative addition complex (Figure 3). Other potential aryl containing drugs or drugderivatives are shown in Figure 4.
As the paragraph descriping shows that 787618-22-8 is playing an increasingly important role.
Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; BUCHWALD, Stephen, L.; PENTELUTE, Bradley, L.; ZHANG, Chi; (170 pag.)WO2017/151910; (2017); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate